Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2022-10-17 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
关于开立募集资金专项账户并签署募集资金监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the opening of special accounts for raised funds and the signing of supervision agreements related to the management and use of those funds. It details the amount of funds raised, the banks involved, the regulatory approvals, and the terms of the supervision agreements. There are no financial statements, earnings data, or management discussion of results. The document is primarily about fundraising and the regulatory compliance around the use of those funds. It is not a full financial report, audit report, or earnings release. It is an update on capital raising and the management of those funds, which fits the category of Capital/Financing Update (CAP). The document length is about 4790 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the best classification is CAP with high confidence.
2022-10-17 Chinese
第二届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 10th meeting of the 2nd Board of Directors of Enwei Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and references to related announcements on a regulatory information website. The content focuses on board decisions such as adjustments to fundraising investment amounts, use of funds, amendments to company articles, and proposals for shareholder meetings. There is no detailed financial data, earnings information, or full report content. The document is a formal board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is 2524 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the classification is MANG with high confidence.
2022-10-17 Chinese
关于变更注册资本、公司类型及修订《公司章程》并办理工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Enwei Pharmaceutical Co., Ltd. regarding changes in registered capital, company type, and amendments to the company's articles of association. It includes specifics about the capital increase following a public offering, changes in company structure, and detailed revisions to the corporate charter. The document also mentions that these changes require shareholder approval at a general meeting and subsequent registration with the relevant authorities. This type of document is a formal announcement related to corporate governance and capital structure changes, not a full annual or interim financial report, nor a simple notice or proxy statement. It is not a transcript, earnings release, or legal proceeding report. The document is comprehensive and regulatory in nature but primarily focuses on corporate governance and capital changes. Therefore, the best fitting category is "Capital/Financing Update (CAP)" as it deals with capital increase, company type change, and related governance amendments tied to financing activities.
2022-10-17 Chinese
中信证券股份有限公司关于恩威医药股份有限公司使用部分闲置募集资金与部分闲置自有资金进行现金管理事项的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the use of idle raised funds and idle own funds by Enwei Pharmaceutical Co., Ltd. for cash management purposes. It references regulatory guidelines related to the management and use of raised funds, details the amount and purpose of the cash management, investment types, risk control measures, and approvals by the board and independent directors. The document is not a full financial report but rather a formal verification and opinion on a specific financial management activity related to raised funds. It does not contain financial statements or quarterly/yearly financial results. It is not an announcement of voting results or a proxy statement, but a regulatory compliance and verification document. Given the nature of the content and the detailed verification opinion, this fits best under Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles or regulatory compliance verifications excluding full annual reports. FY 2022
2022-10-17 Chinese
中信证券股份有限公司关于恩威医药股份有限公司调整募集资金投资项目拟投入募集资金金额事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal opinion from CITIC Securities regarding the adjustment of the amount of raised funds to be invested in projects by Enwei Pharmaceutical Co., Ltd. It references regulatory approvals, fundraising details, and adjustments to the use of proceeds from an IPO. The document includes detailed financial figures about the fundraising and investment adjustments, but it is primarily a verification and opinion letter from the sponsor institution rather than a full financial report or earnings release. It does not contain comprehensive financial statements or management discussion and analysis. The document length is 2434 characters, which is relatively short and focused on the verification of fundraising use. This fits the profile of a Regulatory Filing (RNS) as it is a compliance-related disclosure and verification document rather than a full report or announcement of results. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-10-17 Chinese
监事会议事规则
Governance Information Classification · 95% confidence The document is titled '监事会议事规则' which translates to 'Supervisory Board Meeting Rules' and details the rules and procedures for the supervisory board of the company. It references relevant laws and company articles of association, and outlines governance practices related to the supervisory board's composition, meetings, powers, and decision-making processes. There is no financial data, audit information, or report content. It is a governance document describing internal rules and structure of the supervisory board, which fits the definition of Governance Information (CGR). The document length is 2659 characters, which is relatively short but contains substantive governance content, not just an announcement or notice. Therefore, the appropriate classification is CGR with high confidence.
2022-10-17 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.